JPWO2019157273A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019157273A5 JPWO2019157273A5 JP2020542858A JP2020542858A JPWO2019157273A5 JP WO2019157273 A5 JPWO2019157273 A5 JP WO2019157273A5 JP 2020542858 A JP2020542858 A JP 2020542858A JP 2020542858 A JP2020542858 A JP 2020542858A JP WO2019157273 A5 JPWO2019157273 A5 JP WO2019157273A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- pharmaceutically acceptable
- carboxylic acid
- acceptable salt
- difluoromethylenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims description 66
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 claims description 36
- 208000024891 symptom Diseases 0.000 claims description 20
- 206010011878 Deafness Diseases 0.000 claims description 17
- 231100000895 deafness Toxicity 0.000 claims description 16
- 208000016354 hearing loss disease Diseases 0.000 claims description 16
- 208000009205 Tinnitus Diseases 0.000 claims description 15
- 231100000886 tinnitus Toxicity 0.000 claims description 15
- 230000000699 topical effect Effects 0.000 claims description 13
- 230000001154 acute effect Effects 0.000 claims description 8
- 230000001953 sensory effect Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 238000000034 method Methods 0.000 description 99
- CBSRETZPFOBWNG-UCORVYFPSA-N (1s,3s)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid Chemical compound N[C@H]1C[C@@H](C(O)=O)CC1=C(F)F CBSRETZPFOBWNG-UCORVYFPSA-N 0.000 description 30
- 206010012335 Dependence Diseases 0.000 description 18
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 10
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 10
- 208000000323 Tourette Syndrome Diseases 0.000 description 10
- 208000016620 Tourette disease Diseases 0.000 description 10
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 10
- 208000027530 Meniere disease Diseases 0.000 description 9
- 206010013663 drug dependence Diseases 0.000 description 6
- 208000013403 hyperactivity Diseases 0.000 description 6
- 210000005069 ears Anatomy 0.000 description 4
- 208000011117 substance-related disease Diseases 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 208000029197 Amphetamine-Related disease Diseases 0.000 description 2
- 208000022497 Cocaine-Related disease Diseases 0.000 description 2
- 208000010235 Food Addiction Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010057852 Nicotine dependence Diseases 0.000 description 2
- 208000026251 Opioid-Related disease Diseases 0.000 description 2
- 206010034158 Pathological gambling Diseases 0.000 description 2
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 2
- 208000025569 Tobacco Use disease Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 201000006145 cocaine dependence Diseases 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 201000005040 opiate dependence Diseases 0.000 description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 description 2
- 208000015891 sexual disease Diseases 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862628020P | 2018-02-08 | 2018-02-08 | |
| US62/628,020 | 2018-02-08 | ||
| US201862628541P | 2018-02-09 | 2018-02-09 | |
| US62/628,541 | 2018-02-09 | ||
| PCT/US2019/017201 WO2019157273A1 (en) | 2018-02-08 | 2019-02-08 | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512920A JP2021512920A (ja) | 2021-05-20 |
| JP2021512920A5 JP2021512920A5 (https=) | 2022-02-15 |
| JPWO2019157273A5 true JPWO2019157273A5 (https=) | 2022-02-15 |
Family
ID=67475310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542858A Pending JP2021512920A (ja) | 2018-02-08 | 2019-02-08 | 耳鳴、急性感音性難聴、メニエール病、トゥレット症候群、注意欠陥多動性障害、および嗜癖の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10653652B2 (https=) |
| EP (1) | EP3735237A4 (https=) |
| JP (1) | JP2021512920A (https=) |
| KR (3) | KR20210007948A (https=) |
| CN (1) | CN112261938A (https=) |
| AU (1) | AU2019216742B2 (https=) |
| CA (1) | CA3090258A1 (https=) |
| IL (1) | IL276287A (https=) |
| MX (1) | MX2020008359A (https=) |
| WO (1) | WO2019157273A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE061437T2 (hu) | 2015-10-23 | 2023-06-28 | Navitor Pharm Inc | A Sestrin-GATOR2 kölcsönhatás modulátorai és ezek alkalmazásai |
| US10912750B2 (en) | 2017-04-26 | 2021-02-09 | Navitor Pharmaceuticals, Inc. | Modulators of Sestrin-GATOR2 interaction and uses thereof |
| US11771671B2 (en) | 2018-02-08 | 2023-10-03 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction |
| MX2020010302A (es) * | 2018-03-29 | 2021-01-08 | Ovid Therapeutics Inc | Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares. |
| CN113164414A (zh) | 2018-10-24 | 2021-07-23 | 纳维托制药有限公司 | 多晶型化合物和其用途 |
| CA3156436A1 (en) * | 2019-11-01 | 2021-05-06 | Steven LEVENTER | Methods of treatment using an mtorc1 modulator |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) * | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| US6656172B1 (en) * | 2002-09-27 | 2003-12-02 | Medtronic, Inc. | Method for treating severe tinnitus |
| EP1954316A1 (en) * | 2005-11-28 | 2008-08-13 | Orexigen Therapeutics, Inc. | Methods of treating anxiety disorders |
| CA2790820A1 (en) | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
| WO2012042314A1 (en) | 2010-10-02 | 2012-04-05 | Link Research & Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
| US20140315992A1 (en) | 2011-07-07 | 2014-10-23 | The Children's Hospital Of Philadelphia | Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism |
| EP2790686B1 (en) | 2011-12-12 | 2021-03-10 | Zilentin Ag | Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system |
| EP2806867A4 (en) * | 2012-01-27 | 2015-09-02 | Catalyst Pharmaceutical Partners Inc | METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS |
| EP3341355B1 (en) | 2015-10-09 | 2020-09-30 | Northwestern University | (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma |
| EP4692048A3 (en) | 2017-02-08 | 2026-04-01 | Ovid Therapeutics Inc. | Methods of treating cdkl5 disorders with the compound ov329 |
-
2019
- 2019-02-08 CA CA3090258A patent/CA3090258A1/en active Pending
- 2019-02-08 JP JP2020542858A patent/JP2021512920A/ja active Pending
- 2019-02-08 AU AU2019216742A patent/AU2019216742B2/en active Active
- 2019-02-08 US US16/270,856 patent/US10653652B2/en active Active
- 2019-02-08 WO PCT/US2019/017201 patent/WO2019157273A1/en not_active Ceased
- 2019-02-08 MX MX2020008359A patent/MX2020008359A/es unknown
- 2019-02-08 KR KR1020207025754A patent/KR20210007948A/ko not_active Ceased
- 2019-02-08 KR KR1020257038778A patent/KR20250167147A/ko active Pending
- 2019-02-08 KR KR1020247034793A patent/KR20240154700A/ko not_active Ceased
- 2019-02-08 EP EP19750667.8A patent/EP3735237A4/en active Pending
- 2019-02-08 CN CN201980023215.6A patent/CN112261938A/zh active Pending
-
2020
- 2020-07-26 IL IL276287A patent/IL276287A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512920A5 (https=) | ||
| JP2017509686A5 (https=) | ||
| JP2019031502A5 (https=) | ||
| JP2003523405A (ja) | 睡眠改善のための方法および組成物 | |
| JP2003504303A5 (https=) | ||
| JP2025512831A (ja) | 認知機能障害の治療 | |
| BG108379A (bg) | Използване на енантиомерно чист есциталопрам | |
| BRPI0414347A (pt) | associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade | |
| JP2009517393A (ja) | 不安症の治療方法 | |
| JP2005508872A5 (https=) | ||
| KR20250167147A (ko) | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 | |
| JP2009500420A (ja) | エスゾピクロン及びｏ−デスメチルベンラファキシンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法 | |
| JP2009500421A (ja) | エスゾピクロン及び抗うつ薬の組み合わせ | |
| JPWO2019157273A5 (https=) | ||
| TWI313599B (en) | Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg | |
| JP2011516604A (ja) | 鬱病患者の自殺行動の予防治療のためのミルナシプラン塩酸塩の（１ｓ，２ｒ）鏡像異性体の使用 | |
| JP2007505156A5 (https=) | ||
| FR2804322A1 (fr) | Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies | |
| Suwaki et al. | Nasal speaking valve: a device for managing velopharyngeal incompetence 1 | |
| JP2026510117A (ja) | うつ状態の神経調節と薬理学的治療とを組み合わせたシステム、デバイス、及び方法 | |
| JP2010523662A (ja) | 睡眠関連呼吸障害を処置するための方法及び組成物 | |
| JP2024059812A (ja) | 鏡像異性体的に濃縮された、または純粋なブプロピオンの剤形および方法 | |
| JP2008507550A5 (https=) | ||
| US20230135373A1 (en) | Methods and compositions for treating sleep apnea | |
| Cameron | The Use of Tofrānil in the Aged |